GLP1Base
Menu

Regulator: Therapeutic Goods Administration (TGA), Australian Government Department of Health, Disability and Ageing

GLP-1 drugs and peptides in Australia

In Australia, the Therapeutic Goods Administration (TGA) decides which medicines can be sold. Ozempic, Wegovy and Mounjaro are approved. Pharmacists have not been allowed to make their own copies of GLP-1 drugs since 1 October 2024. Most "peptides" sold online, like BPC-157, are not approved, and the TGA is now acting against people who import, sell or advertise them. Ads for prescription medicines, including weight-loss injections, are banned.

Last verified 2026-09-29 · how we verify

Official regulator site

GLP-1 medicines

Approved products (ARTG entry dates): Victoza 26 Aug 2010; Trulicity 19 Jan 2015; Saxenda 24 Dec 2015; Ozempic 28 Aug 2019; Rybelsus 7 Feb 2022; Wegovy 1 Sep 2022 (adolescent use from 29 Feb 2024); Mounjaro 23 Dec 2022 (type 2 diabetes) and 10 Sep 2024 (weight management). Generic liraglutide pens entered the ARTG on 12 Mar 2025. Orforglipron is under TGA evaluation (accepted Jan 2026). Extra Mounjaro and Ozempic uses are also under evaluation. Compounding: since 1 Oct 2024 pharmacists must not compound GLP-1 receptor agonist analogues. Funding: PBS lists semaglutide injection (Ozempic) and dulaglutide for type 2 diabetes. PBAC recommended Wegovy for established cardiovascular disease with obesity in Nov 2025, but the PBS record as at 1 Sep 2026 shows the listing had not occurred; Novo Nordisk has lodged a revised proposal (established atherosclerotic cardiovascular disease with a BMI of 35 or more) for the November 2026 PBAC meeting. PBAC recommended Mounjaro for type 2 diabetes in Mar 2026, but the sponsor advised it is not proceeding. PBAC's Nov 2025 advice on obesity priority groups favours a slow, managed roll-out. Enforcement: TGA infringement notices to telehealth businesses for advertising weight-loss medicines (July 2024, February 2026), and Ahpra's Sept 2026 warning about unsafe prescribing of GLP-1 weight-loss drugs.

Peptides

Unapproved peptides are unapproved therapeutic goods: not on the ARTG, not assessed by the TGA. Importing, advertising, manufacturing, supplying and exporting them is unlawful unless an exemption applies, and TGA states influencers, affiliates and online sellers may be held accountable. Scheduling: BPC-157 has been Schedule 4 and Appendix D clause 5 (possession without authority illegal) since 1 Jun 2024. TB500, thymosin beta 4, CJC-1295, AOD9604, ipamorelin, growth hormone releasing peptides and secretagogues are also in Appendix D clause 5; sermorelin and Melanotan II are named in Schedule 4 only, but sermorelin is a GHRH analogue and the Appendix D clause 5 entry covers GHRHs "including those separately specified in Schedule 4", so the possession control may also apply to it. Many others (for example KPV, MOTS-c, semax, selank, epitalon, kisspeptin, DSIP, LL-37) are not named in the Poisons Standard and have no ARTG product. GHK-Cu is not named either, but Schedule 4 covers copper compounds for human use (with exceptions for low-copper preparations). Compounding: individual-patient compounding is exempt from ARTG inclusion, but pharmacists and doctors must meet manufacturing-licence exemption rules, and the exemption does not cover GLP-1 receptor agonist analogues. Import: the Personal Importation Scheme requires clear labelling, and for prescription-only goods a valid Australian prescription or written authority; the TGA will not release unmarked or code-only vials. Enforcement timeline 2026: 26 Mar to 17 Apr ABF-led operation with the TGA and Victoria Police seizing steroids and peptide products worth over $2 million, with three people charged with importing performance and image enhancing drugs (further charges announced 13 Aug); 13 Apr safety advisory naming BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295; 10 Jun peptides added as a compliance priority; 19 Jun joint TGA and Chief Medical Officer warning; 20 Jul notice to promoters; 17 Aug seizure of over $120,000 of peptides and steroids in NSW; 14 Sep alert that a product sold as retatrutide contained semaglutide; 28 Sep Federal Court proceedings over alleged peptide advertising; 21 May and 17 Aug actions on Melanotan II. Sport: Sport Integrity Australia lists BPC-157 as a non-approved (S0) example and sermorelin and ipamorelin as banned peptide hormones (S2); athletes should confirm any substance with them.

Advertising rules

Advertising prescription-only medicines to the public is prohibited under the Therapeutic Goods Act 1989, except in very limited circumstances. TGA guidance published 18 Jun 2026 says direct or indirect references count: terms such as "weight loss injection", images of an injection pen, business names that point to a medicine, and telehealth pages that present a service as a way to obtain a specific prescription medicine can all be unlawful advertising. Unapproved goods generally cannot be advertised to the public, and advertising of compounded medicines is restricted. Health services that involve therapeutic goods are also regulated by the TGA and by Ahpra advertising rules. Penalties: civil penalties up to $1.82 million per breach for individuals and $18.2 million for corporations, criminal penalties up to 7 years imprisonment, plus infringement notices. Enforcement examples: 21 notices totalling $319,260 to 4 businesses and 3 individuals, including telehealth clinics (July 2024); Prime Medic notices for advertising Ozempic and Mounjaro (paid January 2026); Federal Court action over alleged peptide advertising (September 2026).

Every molecule in Australia

MoleculeStatusWhat it meansVerified
AmycretinNot approvedInvestigational only. No amycretin product is on the ARTG and no application appears on the TGA's evaluation list.Details →source2026-09-29
AOD-9604ProhibitedUnapproved and controlled: AOD9604 is prescription-only and possession without authority is illegal under the Poisons Standard.Details →source2026-09-29
BPC-157ProhibitedUnapproved and tightly controlled: prescription-only, possession without authority is illegal since 1 June 2024, and the TGA has taken an alleged advertiser to court.Details →source2026-09-29
Bremelanotide (PT-141)Not approvedNot on the ARTG and not shown as under TGA evaluation. It is an unapproved therapeutic good in Australia.Details →source2026-09-29
Cagrilintide (and CagriSema)Not approvedNot approved and not shown as under TGA evaluation. No cagrilintide product is on the ARTG.Details →source2026-09-29
CJC-1295ProhibitedUnapproved and controlled: CJC-1295 is prescription-only, possession without authority is illegal, and the TGA has named and seized it.Details →source2026-09-29
DSIP (delta sleep-inducing peptide)Not approvedNo DSIP product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
DulaglutideApprovedApproved as Trulicity for type 2 diabetes since January 2015 and listed on the PBS. Compounded GLP-1 copies are barred.Details →source2026-09-29
EcnoglutideNot approvedNot approved in Australia. No ecnoglutide product is on the ARTG and no application appears on the TGA's evaluation list.Details →source2026-09-29
Elamipretide (SS-31)Not approvedNo elamipretide product is on the ARTG and none appears on the TGA's evaluation list.Details →source2026-09-29
EloralintideNot approvedInvestigational only. No eloralintide product is on the ARTG and no application appears on the TGA's evaluation list.Details →source2026-09-29
EpitalonNot approvedNo epitalon product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
ExenatideNot approvedTGA assessed Byetta and Bydureon (2013), but a search of the ARTG on 29 Sep 2026 finds no current exenatide entry.Details →source2026-09-29
GHK-Cu (copper peptide)Not approvedNot on the ARTG. The TGA names GHK-Cu as an unapproved peptide product and warns against importing or advertising it.Details →source2026-09-29
IpamorelinProhibitedUnapproved and controlled: ipamorelin is prescription-only and possession without authority is illegal under the Poisons Standard.Details →source2026-09-29
KisspeptinNot approvedNo kisspeptin product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
KPVNot approvedNo KPV product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
LiraglutideGenerics availableApproved as Victoza and Saxenda; generic liraglutide pens were added to the ARTG from March 2025. Compounded versions barred since 1 October 2024.Details →source2026-09-29
LL-37Not approvedNo LL-37 product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
Maridebart cafraglutide (MariTide)Not approvedInvestigational only. No maridebart cafraglutide product is on the ARTG and no application appears on the TGA's evaluation list.Details →source2026-09-29
MazdutideNot approvedNot approved in Australia. No mazdutide product is on the ARTG and no application appears on the TGA's evaluation list.Details →source2026-09-29
Melanotan IIProhibitedNot approved for any use. Melanotan II is prescription-only, has no ARTG product, and a seller was issued 27 TGA infringement notices (paid May 2026).Details →source2026-09-29
MOTS-cNot approvedNo MOTS-c product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
NAD+Not approvedNo injectable NAD+ product is approved. ARTG entries that name NAD (nadide) are export-only listings that must not be supplied in Australia.Details →source2026-09-29
OrforglipronUnder reviewNot yet approved. Eli Lilly's application for weight management and type 2 diabetes was accepted by the TGA in January 2026 and is under evaluation.Details →source2026-09-29
PramlintideNot approvedNot on the ARTG and no application on the TGA's evaluation list. It could only be reached through unapproved-medicine pathways.Details →source2026-09-29
RetatrutideProhibitedNot approved by the TGA or any comparable regulator. The TGA names retatrutide in peptide warnings and seizures, and a product sold as retatrutide contained semaglutide instead.Details →source2026-09-29
SelankNot approvedNo selank product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
SemaglutideApprovedApproved on the ARTG as Ozempic, Rybelsus and Wegovy. PBS covers Ozempic for type 2 diabetes; Wegovy is not yet PBS-listed. Compounded copies barred since 1 Oct 2024.Details →source2026-09-29
SemaxNot approvedNo semax product is on the ARTG. It counts as an unapproved peptide, and advertising or supplying it is likely unlawful.Details →source2026-09-29
SermorelinNot approvedNot on the ARTG. Sermorelin is prescription-only (Schedule 4), and as a GHRH analogue it may also fall under the Appendix D possession control.Details →source2026-09-29
SetmelanotideNot approvedNo setmelanotide product is on the ARTG and none appears on the TGA's evaluation list. Access would need an unapproved-medicine pathway.Details →source2026-09-29
SurvodutideNot approvedInvestigational only. No survodutide product is on the ARTG and no application appears on the TGA's evaluation list.Details →source2026-09-29
TB-500 (thymosin beta-4 fragment)ProhibitedUnapproved and controlled: TB-500 and thymosin beta 4 are prescription-only, possession without authority is illegal, and the TGA has seized it.Details →source2026-09-29
TesamorelinNot approvedNot on the ARTG. The Poisons Standard lists growth hormone releasing hormones as a prescription-only class with a possession control.Details →source2026-09-29
TirzepatideApprovedApproved as Mounjaro for type 2 diabetes (Dec 2022) and weight management (Sep 2024). Not PBS-listed: the sponsor is not proceeding for now. Compounding barred since Oct 2024.Details →source2026-09-29

For experts

The regulatory detail

Therapeutic goods must be on the Australian Register of Therapeutic Goods (ARTG) before they are supplied, unless an exemption applies. Scheduling under the Poisons Standard (June 2026 edition) is given legal effect by state and territory law; semaglutide, tirzepatide, liraglutide, dulaglutide and exenatide are Schedule 4. Compounded medicines are unapproved goods that may be supplied for an individual patient on a prescription or request, but from 1 October 2024 pharmacists must not compound GLP-1 receptor agonist analogues. The Personal Importation Scheme allows import of unapproved goods for personal or immediate-family use, but prescription-only goods need a valid Australian prescription and unlabelled or unclear vials are not released. Public subsidy runs through PBAC and the PBS: the PBS records seen on 29 September 2026 show no listing of a GLP-1 for obesity; PBAC recommended Wegovy for people with established cardiovascular disease and obesity in November 2025 (a revised proposal is on the November 2026 PBAC agenda), and the Mounjaro type 2 diabetes listing has stalled because the sponsor is not proceeding. Since June 2026 unapproved peptides are a TGA compliance priority, with seizures, criminal import charges, infringement notices and Federal Court proceedings reported between April and September 2026, and Ahpra issued new prescriber guidance on 16 September 2026.

Official sources we monitor

Recent changes in Australia

  1. 2025-12-19

    Australia's PBAC publishes advice on subsidising GLP-1 obesity treatments

    The Pharmaceutical Benefits Advisory Committee published its November 2025 outcome on 19 December 2025. It advised a slow, managed roll-out to priority groups such as people with established cardiovascular disease, and separately recommended listing Wegovy on the PBS for people with established cardiovascular disease and obesity.

  2. 2024-05-22

    Australia announces a ban on compounded GLP-1 medicines, effective 1 October 2024

    Health Minister Mark Butler announced on 22 May 2024 that compounded copies of GLP-1 medicines such as Ozempic and Mounjaro would be removed from the pharmacy compounding exemption from 1 October 2024. The Minister said at least 20,000 Australians were using such products at the time.

Full timeline →

Sources (84)

  1. 01Manufacturing, supplying and advertising compounded medicines lawfullyTherapeutic Goods Administration (TGA) · 2026-05-14 · accessed 2026-09-29
  2. 02Compounded medicinesTherapeutic Goods Administration (TGA) · 2026-05-14 · accessed 2026-09-29
  3. 03Therapeutic Goods (Poisons Standard - June 2026) Instrument 2026Federal Register of Legislation (Australian Government) · 2026-05 · accessed 2026-09-29
  4. 04The Poisons Standard (the SUSMP)Therapeutic Goods Administration (TGA) · 2026-06-01 · accessed 2026-09-29
  5. 05Notice of final decision to amend (or not amend) the current Poisons Standard - ACMS #43, ACCS #37, Joint ACMS-ACCS #35 (BPC-157)Therapeutic Goods Administration (TGA) · 2024-05-22 · accessed 2026-09-29
  6. 06Personal Importation SchemeTherapeutic Goods Administration (TGA) · 2026-09-08 · accessed 2026-09-29
  7. 07New packaging rules for personal importsTherapeutic Goods Administration (TGA) · 2026-09-08 · accessed 2026-09-29
  8. 08Understanding your responsibilities when importing, compounding and supplying unapproved peptide productsTherapeutic Goods Administration (TGA) · 2026-04-13 · accessed 2026-09-29
  9. 09TGA warning on the risks of importing unapproved peptide productsTherapeutic Goods Administration (TGA) · 2026-05-07 · accessed 2026-09-29
  10. 10Concerns regarding the public health risks associated with unapproved peptide productsTherapeutic Goods Administration (TGA) · 2026-06-19 · accessed 2026-09-29
  11. 11TGA strengthens compliance focus on unapproved peptide products as part of evolving risk responseTherapeutic Goods Administration (TGA) · 2026-06-10 · accessed 2026-09-29
  12. 12Unapproved peptide product promoters and suppliers are put on noticeTherapeutic Goods Administration (TGA) · 2026-07-20 · accessed 2026-09-29
  13. 13TGA flexes its muscle against illegal peptides and steroidsTherapeutic Goods Administration (TGA) · 2026-08-17 · accessed 2026-09-29
  14. 14Former company and directors behind BioV8 to face court for alleged unlawful advertising of peptidesTherapeutic Goods Administration (TGA) · 2026-09-28 · accessed 2026-09-29
  15. 15TGA tests counterfeit retatrutide product following serious adverse event reportTherapeutic Goods Administration (TGA) · 2026-09-14 · accessed 2026-09-29
  16. 16Individual issued 27 infringement notices for allegedly supplying Melanotan IITherapeutic Goods Administration (TGA) · 2026-05-21 · accessed 2026-09-29
  17. 17Complying with the restrictions on advertising prescription medicines to the publicTherapeutic Goods Administration (TGA) · 2026-06-18 · accessed 2026-09-29
  18. 18TGA releases new guidance on advertising restrictions for prescription medicinesTherapeutic Goods Administration (TGA) · 2026-06-18 · accessed 2026-09-29
  19. 19Telehealth businesses fined over $300,000 for alleged unlawful advertising of weight loss medicinesTherapeutic Goods Administration (TGA) · 2024-07-12 · accessed 2026-09-29
  20. 20Prime Medic Group issued infringement notices for alleged unlawful advertising of weight loss medicinesTherapeutic Goods Administration (TGA) · 2026-02-02 · accessed 2026-09-29
  21. 21Crackdown on reckless prescribing as regulator ramps up peptides oversightMedical Board of Australia / Ahpra · 2026-09-16 · accessed 2026-09-29
  22. 22Prohibited List ExplainedSport Integrity Australia · 2026 · accessed 2026-09-29
  23. 23Prescription medicines under evaluation (last updated 21 September 2026)Therapeutic Goods Administration (TGA) · 2026-09-21 · accessed 2026-09-29
  24. 24Prescription medicines under evaluation: orforglipron calcium (Eli Lilly Australia Pty Ltd, accepted January 2026)Therapeutic Goods Administration (TGA) · 2026-01 · accessed 2026-09-29
  25. 25PBS Medicines Status: semaglutide (Wegovy), established cardiovascular disease with obesityAustralian Government Department of Health, Disability and Ageing (PBS) · 2026-07-23 · accessed 2026-09-29
  26. 26PBS Medicines Status: tirzepatide (Mounjaro), type 2 diabetes mellitusAustralian Government Department of Health, Disability and Ageing (PBS) · 2026-06-30 · accessed 2026-09-29
  27. 27PBS Medicines Status: semaglutide (Ozempic), type 2 diabetes mellitusAustralian Government Department of Health, Disability and Ageing (PBS) · 2026-03-31 · accessed 2026-09-29
  28. 28PBAC advice on equitable access to GLP-1 obesity treatmentsAustralian Government Department of Health, Disability and Ageing (PBS) · 2026-03-17 · accessed 2026-09-29
  29. 29MOUNJARO tirzepatide solution for injection pre-filled pen (ARTG 379330)Therapeutic Goods Administration (TGA) · 2022-12 · accessed 2026-09-29
  30. 30WEGOVY semaglutide solution for injection pre-filled pen (ARTG 356286)Therapeutic Goods Administration (TGA) · 2022-09 · accessed 2026-09-29
  31. 31OZEMPIC semaglutide solution for injection pre-filled pen (ARTG 308324)Therapeutic Goods Administration (TGA) · 2019-08 · accessed 2026-09-29
  32. 32RSS feedsTherapeutic Goods Administration (TGA) · 2026-08-25 · accessed 2026-09-29
  33. 33PBS Medicines Status: semaglutide (Wegovy), established atherosclerotic cardiovascular disease with obesity (November 2026 PBAC meeting)Australian Government Department of Health, Disability and Ageing (PBS) · 2026-07-23 · accessed 2026-09-29
  34. 34Three Victorians arrested following seizure of over $2 million worth of steroids and peptides by the ABF and TGATherapeutic Goods Administration (TGA) · 2026-04-17 · accessed 2026-09-29
  35. 35Two Victorians charged with further offences related to alleged importation of illicit performance and image enhancing drugsTherapeutic Goods Administration (TGA) · 2026-08-13 · accessed 2026-09-29
  36. 36Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (BioDrugs 1999;12(2):139-57)BioDrugs (Adis) · 1999-08 · accessed 2026-09-29
  37. 37ARTG keyword search for 'amycretin' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  38. 38Access pathways for unapproved therapeutic goodsTherapeutic Goods Administration (TGA) · 2025-10 · accessed 2026-09-29
  39. 39ARTG keyword search for 'AOD-9604' (1177 loose-match results, all pages checked; none is a AOD-9604 product)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  40. 40ARTG keyword search for 'bremelanotide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  41. 41ARTG keyword search for 'cagrilintide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  42. 42ARTG keyword search for 'CJC-1295' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  43. 43ARTG keyword search for 'DSIP' (138 loose-match results, all pages checked; none is a DSIP product)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  44. 44TRULICITY dulaglutide solution for injection prefilled pen (ARTG 217965)Therapeutic Goods Administration (TGA) · 2015-01 · accessed 2026-09-29
  45. 45PBS A-Z medicine listing: D (includes dulaglutide)Australian Government Department of Health, Disability and Ageing (PBS) · 2026-09 · accessed 2026-09-29
  46. 46ARTG keyword search for 'ecnoglutide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  47. 47ARTG keyword search for 'elamipretide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  48. 48Access to unapproved therapeutic goods for individual patients (Special Access Scheme)Therapeutic Goods Administration (TGA) · 2025-12-03 · accessed 2026-09-29
  49. 49ARTG keyword search for 'eloralintide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  50. 50ARTG keyword search for 'epitalon' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  51. 51AusPAR: Byetta / Bydureon (exenatide)Therapeutic Goods Administration (TGA) · 2013-03-27 · accessed 2026-09-29
  52. 52ARTG keyword search for 'exenatide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  53. 53ARTG keyword search for 'GHK' (2081 loose-match results, all pages checked; none is a GHK product)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  54. 54ARTG keyword search for 'ipamorelin' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  55. 55ARTG keyword search for 'kisspeptin' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  56. 56ARTG keyword search for 'KPV' (283 loose-match results, all pages checked; none is a KPV product)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  57. 57VICTOZA liraglutide solution for injection pre-filled pen (ARTG 153980)Therapeutic Goods Administration (TGA) · 2010-08 · accessed 2026-09-29
  58. 58SAXENDA liraglutide solution for injection pre-filled pen (ARTG 225804)Therapeutic Goods Administration (TGA) · 2015-12 · accessed 2026-09-29
  59. 59LIRAGLUTIDE SANDOZ liraglutide solution for injection pre-filled pen (ARTG 449145)Therapeutic Goods Administration (TGA) · 2025-03 · accessed 2026-09-29
  60. 60ARTG keyword search for 'LL-37' (55 loose-match results, all pages checked; none is a LL-37 product)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  61. 61ARTG keyword search for 'maridebart' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  62. 62ARTG keyword search for 'mazdutide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  63. 63Melanotan II tanning peptide products found to be inconsistently dosedTherapeutic Goods Administration (TGA) · 2026-08-17 · accessed 2026-09-29
  64. 64ARTG keyword search for 'MOTS-c' (14 loose-match results, all pages checked; none is a MOTS-c product)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  65. 65ARTG keyword search for 'nadide' (13 entries, export-only category)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  66. 66SL-NAD+ (ARTG 371660), Medicine Listed (Export Only)Therapeutic Goods Administration (TGA) · 2021-07 · accessed 2026-09-29
  67. 67Public Summary: ARTG entry 371660 SL-NAD+, Medicine Listed (Export Only)Therapeutic Goods Administration (TGA) · 2021-07-26 · accessed 2026-09-29
  68. 68ARTG keyword search for 'orforglipron' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  69. 69ARTG keyword search for 'pramlintide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  70. 70ARTG keyword search for 'retatrutide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  71. 71ARTG keyword search for 'selank' (49 loose-match results, all pages checked; none is a selank product)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  72. 72RYBELSUS semaglutide tablet blister pack (ARTG 346198)Therapeutic Goods Administration (TGA) · 2022-02 · accessed 2026-09-29
  73. 73AusPAR: Wegovy (semaglutide), extension of indication (weight management in adolescents aged 12 and over; ARTG entry 29 February 2024)Therapeutic Goods Administration (TGA) · 2024-09-05 · accessed 2026-09-29
  74. 74Prescription medicines under evaluation: Ozempic (semaglutide), claudication in peripheral arterial disease (accepted September 2025)Therapeutic Goods Administration (TGA) · 2025-09 · accessed 2026-09-29
  75. 75ARTG keyword search for 'semax' (33 loose-match results, all pages checked; none is a semax product)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  76. 76ARTG keyword search for 'sermorelin' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  77. 77ARTG keyword search for 'setmelanotide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  78. 78ARTG keyword search for 'survodutide' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  79. 79ARTG keyword search for 'TB-500' (11 loose-match results, all pages checked; none is a TB-500 product)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  80. 80ARTG keyword search for 'tesamorelin' (no matching results)Therapeutic Goods Administration (TGA) · 2026-09-29 · accessed 2026-09-29
  81. 81AusPAR: Mounjaro (tirzepatide), new chemical entityTherapeutic Goods Administration (TGA) · 2023-11-16 · accessed 2026-09-29
  82. 82AusPAR: Mounjaro (tirzepatide), extension of indications (chronic weight management)Therapeutic Goods Administration (TGA) · 2024-09-26 · accessed 2026-09-29
  83. 83Prescription medicines under evaluation: Mounjaro (tirzepatide), proposed use from age 10 (accepted September 2025)Therapeutic Goods Administration (TGA) · 2025-09 · accessed 2026-09-29
  84. 84Prescription medicines under evaluation: Mounjaro (tirzepatide), cardiovascular risk reduction (accepted December 2025)Therapeutic Goods Administration (TGA) · 2025-12 · accessed 2026-09-29